Loading organizations...
§ Private Profile · Watertown, MA, USA
Develops oral ultra-long-acting and sustained-release therapies.
Lyndra Therapeutics has raised $352.8M across 7 funding rounds.
Lyndra Therapeutics has raised $352.8M in total across 7 funding rounds.
Lyndra Therapeutics has raised $352.8M in total across 7 funding rounds.
Lyndra Therapeutics's investors include Sarissa Capital, Polaris Partners, Sun Pharmaceutical Industries, Geoffrey Cornell, CFA, Catalytic Impact Foundation, Gilead Sciences, HOPU Investments, Invus, Limitless Ventures, Mass General Brigham Ventures, Quark Venture, Yipinhong Pharmaceutical (USA).
Lyndra Therapeutics has raised $352.8M across 7 funding rounds. Most recently, it raised $101.0M Series E in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 21, 2023 | $101M Series E | Sarissa Capital | Polaris Partners, SUN Pharmaceutical Industries | Announced |
| Jun 14, 2023 | $20.3M Venture Round | — | — | Announced |
| Jun 24, 2021 | $60.5M Series C | Geoffrey Cornell, CFA | Catalytic Impact Foundation, Gilead Sciences, Hopu Investments, Invus, Limitless Ventures, Mass General Brigham Ventures, Polaris Partners, Quark Venture, Yipinhong Pharmaceutical (usa) | Announced |
| Jul 30, 2019 | $13M Grant | Bill & Melinda Gates Foundation | — | Announced |
| Jan 29, 2019 | $55M Series B | — | Bill & Melinda Gates Foundation, Gilead Sciences, Cliff Chau, Invus, Orient Life, Polaris Partners | Announced |
| May 1, 2018 | $80M Venture Round | Karimah ES Sabar | — | Announced |
| Apr 13, 2017 | $23M Series A | Polaris Partners | GF Securities, Healthlink Capital, Mass General Brigham, Quark Venture, Suffolk Equity, Yonghua Capital | Announced |